In June 2025, several breakthrough drugs received their first global approvals and market launches, marking significant advances in therapeutic innovation.
1. Genakumab (Firsekibart)
Firsekibart (Genakumab), developed by Changchun Genescience Pharmaceutical, is a fully human monoclonal antibody targeting interleukin-1β (IL-1β). It functions as an IL-1β inhibitor and was approved in China on June 30, 2025, for the treatment of gouty arthritis, especially in patients who are intolerant or unresp